Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 32Unknown 24Recruiting 14Terminated 6Withdrawn 3Not yet recruiting 3Active not recruiting 3Suspended 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 629Prostatic Neoplasms 372Neoplasms 304Carcinoma, Non-Small-Cell Lung 216Lung Neoplasms 205Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 135Leukemia, Myeloid, Acute 129Neoplasm Metastasis 124Melanoma 116Brain Neoplasms 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 95Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 81Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Triple Negative Breast Neoplasms 75Carcinoma, Renal Cell 75Lymphoma 71Lymphoma, Non-Hodgkin 67Myelodysplastic Syndromes 66

Interventions

Social Determinants of Health 2Prednisone 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Drug-Related Side Effects and Adverse Reactions × Clear all
NCT05096338 2026-03-23

PCT

Abramson Cancer Center at Penn Medicine

Active not recruiting
200 enrolled
Genitourinary

Cardiovascular Diseases, Prostatic Neoplasms, Drug-Related Side Effects and Adverse Reactions, Cardiotoxicity

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT05078190 2025-11-06

CCT2

Abramson Cancer Center at Penn Medicine

Active not recruiting
200 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases, Drug-Related Side Effects and Adverse Reactions, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡